As of 2024-09-12, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (8.03) USD. This relative valuation is based on P/E multiples. With the latest stock price at 261.91 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -103.1%.
The range of the Relative Valuation is (6.54) - (8.94) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 16.0x | 14.4x |
| Forward P/E multiples | 11.1x - 15.7x | 13.9x |
| Fair Price | (6.54) - (8.94) | (8.03) |
| Upside | -102.5% - -103.4% | -103.1% |
| Date | P/E |
| 2024-09-11 | -461.27 |
| 2024-09-10 | -451.23 |
| 2024-09-09 | -445.86 |
| 2024-09-06 | -434.63 |
| 2024-09-05 | -442.90 |
| 2024-09-04 | -445.83 |
| 2024-09-03 | -446.95 |
| 2024-08-30 | -462.65 |
| 2024-08-29 | -505.48 |
| 2024-08-28 | -494.37 |
| 2024-08-27 | -493.59 |
| 2024-08-26 | -474.01 |
| 2024-08-23 | -480.17 |
| 2024-08-22 | -488.43 |
| 2024-08-21 | -491.67 |
| 2024-08-20 | -494.47 |
| 2024-08-19 | -483.41 |
| 2024-08-16 | -472.42 |
| 2024-08-15 | -462.66 |
| 2024-08-14 | -463.00 |
| 2024-08-13 | -471.35 |
| 2024-08-12 | -475.84 |
| 2024-08-09 | -474.68 |
| 2024-08-08 | -476.33 |
| 2024-08-07 | -458.21 |
| 2024-08-06 | -462.42 |
| 2024-08-05 | -466.71 |
| 2024-08-02 | -479.13 |
| 2024-08-01 | -473.07 |
| 2024-07-31 | -418.21 |
| 2024-07-30 | -411.78 |
| 2024-07-29 | -416.13 |
| 2024-07-26 | -413.60 |
| 2024-07-25 | -418.95 |
| 2024-07-24 | -416.49 |
| 2024-07-23 | -412.63 |
| 2024-07-22 | -414.92 |
| 2024-07-19 | -418.86 |
| 2024-07-18 | -416.87 |
| 2024-07-17 | -422.72 |
| 2024-07-16 | -440.00 |
| 2024-07-15 | -451.18 |
| 2024-07-12 | -458.81 |
| 2024-07-11 | -459.71 |
| 2024-07-10 | -453.96 |
| 2024-07-09 | -448.64 |
| 2024-07-08 | -449.30 |
| 2024-07-05 | -442.11 |
| 2024-07-03 | -437.97 |
| 2024-07-02 | -436.09 |